Breaking News Instant updates and real-time market news.

WMT

Walmart

$94.43

0.52 (0.55%)

, X

U.S. Steel

$30.24

-0.24 (-0.79%)

07:35
10/02/18
10/02
07:35
10/02/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Wal-Mart (WMT), US Steel (X), Gilead (GILD), Ctrip.com (CTRP), ArcelorMittal (MT), Neptune Technologies (NEPT), Shire (SHPG), Cree (CREE), and Iridium (IRDM).

WMT

Walmart

$94.43

0.52 (0.55%)

X

U.S. Steel

$30.24

-0.24 (-0.79%)

GILD

Gilead

$77.99

0.77 (1.00%)

CTRP

Ctrip

$37.16

(0.00%)

MT

ArcelorMittal

$31.14

0.28 (0.91%)

NEPT

Neptune Wellness

$4.59

0.72 (18.60%)

SHPG

Shire

$178.12

-3.19 (-1.76%)

CREE

Cree

$37.52

-0.34 (-0.90%)

IRDM

Iridium

$22.65

0.15 (0.67%)

  • 02

    Oct

  • 03

    Oct

  • 22

    Oct

  • 28

    Oct

  • 02

    Nov

  • 15

    Nov

  • 21

    Dec

  • 03

    Mar

WMT Walmart
$94.43

0.52 (0.55%)

09/27/18
MSCO
09/27/18
NO CHANGE
MSCO
Walmart, Kroger to see margin pain from 'war of attrition,' says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said food retail disruption is accelerating as both grocers and consumers head online and he projects that industry EBIT margins, which are "already slim at 3%," could shrink by nearly a third by 2023. He is incrementally more cautious on Kroger (KR) and has "meaningfully" lowered his EBIT and EPS forecasts, stating that while the company and Walmart (WMT) can both take share, "margin pain" is likely in the process of their "war of attrition" in grocery with Amazon (AMZN), each other and a number of additional competitors. Consensus estimates expect stable margins at Kroger and Walmart, which appears challenging to Gutman, he tells investors. The analyst keeps Equal Weight ratings on both traditional retailers and an Overweight rating on Amazon, arguing that it should be able to leverage Prime and its fast-growing high-margin businesses to invest more heavily while still driving higher profitability.
09/25/18
MSCO
09/25/18
NO CHANGE
Target $2500
MSCO
Overweight
Amazon should increase focus on autonomous driving, says Morgan Stanley
Morgan Stanley analyst Brian Nowak makes the case that autonomous driving technology should be where Amazon (AMZN) invests next, stating that Alphabet's (GOOGL) Waymo partnering with Walmart (WMT) and shopping center owner DDR (DDR) to drive shoppers to stores is "just the beginning." He sees the potential for a deeper integration between Google Shopping and Waymo autonomous cars to deliver retailers' in-store or warehouse inventory to consumers, and sees Amazon needing a defense against a stronger potential long-term Waymo retail offering. Nowak also notes that Amazon is already investing in its own delivery network and contends that investing in an autonomous offering is just an extension of this strategy in many ways. Additionally, the analyst sees a small relative upfront investment, the potential for large shipping savings and ways to leverage the value of miles driven. Nowak maintains an Overweight rating and $2,500 price target on Amazon shares.
09/25/18
CLVD
09/25/18
NO CHANGE
CLVD
Neutral
Walmart Q3 comps trending above consens, says at Cleveland Research
Cleveland Research analyst Scott Bender's checks indicate sales trends remain strong for Walmart's Q3-to-date and appear to be trending above consensus expectations with fairly steady trends in grocery despite tough comps. The analyst is modeling Q3 US comp store sales of up 3.5%-4%, versus consensus of up 2.8%.
09/26/18
SBSH
09/26/18
INITIATION
Target $13
SBSH
Neutral
Hostess Brands initiated with a Neutral at Citi
Citi analyst Alexis Borden started Hostess Brands (TWNK) with a Neutral rating and $13 price target. The analyst sees a "host of questions" over Hostess' near-to-medium term outlook due to the recent revenue headwinds from lost Walmart (WMT) display space, heightened cost inflation pressures and continued "sluggish" Sweet Baked Goods category growth. As such, Borden is cautious on the shares near-term.
X U.S. Steel
$30.24

-0.24 (-0.79%)

09/27/18
LBOW
09/27/18
NO CHANGE
Target $49
LBOW
Buy
U.S. Steel estimates lowered on OCTG survey weakness at Longbow
Longbow analyst Chris Olin's latest sruvey of energy metal distributors and traders showed a deceleration in shipment growth reported by OCTG. Olin believes slowing end market demand growth, excess distribution inventories and modestly lower trending spot prices could ultimately limit Tubular Segment upside over the next 2-3 quarters, and when combined with negative momentum in carbon steel, puts $650M EBIT guidance at risk. The analyst lowered U.S. Steel's 2018 earnings forecast to $5.71 from $5.78, but maintains a Buy rating saying the company is positioned for continued earnings growth in 2019 as sheet/tube contracts stabilize at higher levels and US production moves towards 11-12M tons.
08/27/18
08/27/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MORGAN STANLEY DOUBLE DOWNGRADES U.S. STEEL: Morgan Stanley analyst Piyush Sood double downgraded U.S. Steel (X) to Underweight from Overweight as he notes that steel prices are falling and he believes the recent price peak is "firmly behind" the market. Sood lowered his price target on U.S. Steel shares to $30 from $44. He prefers AK Steel (AKS), which he upgraded to Overweight from Equal Weight citing its good free cash flow prospects, and also prefers Steel Dynamics (STLD), which he also upgraded to Overweight from Equal Weight. PAPA JOHN'S UPGRADED TO BUY: Kalinowski Equity Research's Mark Kalinowski upgraded Papa John's (PZZA) to Buy from Neutral as he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. He noted that CNBC reports the company "isn't currently exploring a sale," but he believes a sale makes a lot of sense. BLOOM ENERGY CUT TO UNDERPERFORM: Credit Suisse analyst Michael Weinstein downgraded Bloom Energy (BE) to Underperform from Neutral, with a $24 price target on the stock, on valuation. While the analyst acknowledged the disruptive potential of Bloom Energy's technology, the stock is now trading at a premium. Although the company has shown impressive success so far, much work remains to be done to continue lowering costs and deliver next generation improvements, he contended. WEDBUSH CUTS CHIPOTLE TO UNDERPERFORM: Wedbush analyst Nick Setyan downgraded Chipotle Mexican Grill (CMG) to Underperform from Neutral and lowered his price target for the shares to $445 from $450. Setyan sees increased risk to Chipotle's near-term same-store-sales growth and margin expectations, and continues to see risk to margin expectations through 2020. Quarter-to-date checks suggest risk to the current Q3 consensus same-store-sales growth expectation, Setyan said. Further, the analyst believes that while theoretical drivers towards 2019 same-store-sales growth expectations exist, the risks are underappreciated.
09/04/18
UBSW
09/04/18
NO CHANGE
UBSW
UBS still cautious on steel sector, but says caution already priced into stocks
UBS analyst Andreas Bokkenheuser said he remains cautious on the steel sector and said his research shows there is more imports on flat steel than rolled. That is more negative for US Steel (X) and AK Steel (AKS) than Nucor (NUE) and Steel Dynamics (STLD). He also believes the shares are pricing in a steel price correction already, so he expects the equities to outperform the physical prices.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $35
DBAB
Hold
U.S. Steel downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded U.S. Steel to Hold and lowered his price target for the shares to $35 from $47. The analyst says he's becoming more cautious on steel stocks.
GILD Gilead
$77.99

0.77 (1.00%)

09/13/18
JPMS
09/13/18
INITIATION
Target $140
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
JPMorgan analyst James Quigley started Galapagos NV (GLPG) with an Overweight rating and $140 price target. The company's key value driver is filgotinib, a selective JAK1 inhibitor which has shown potential best in class data in inflammatory diseases and is licensed to Gilead (GILD), Quigley tells investors in a research note. The analyst forecasts peak in market filgotinib sales of EUR 4.4B. Quigley also sees value in Galapagos' wholly owned GLPG1690, which he says could be the first drug to halt disease progression in idiopathic pulmonary fibrosis.
09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
Diplomat Pharmacy weakness on Gilead generics overdone, says JPMorgan
JPMorgan analyst Lisa Gill says the weakness yesterday in shares of Diplomat Pharmacy (DPLO) following Gilead's (GILD) announcement that it will be launching new authorized generic versions of hepatitis C treatments Epclusa and Harvoni is a "significant overreaction." Hepatitis C represents a relatively small portion of revenue for Diplomat Pharmacy, and as such, these two drugs are not material, Gill tells investors in a research note. Further, the analyst believes it is unclear whether payors will adopt the authorized generic in lieu of continuing to receive rebates on the branded drugs. In addition, Gill thinks Diplomat should be able to purchase the new authorized generics at a discount to the new list price with a higher gross margin spread relative to the brand. The analyst keeps an Overweight rating on the shares.
09/25/18
JEFF
09/25/18
INITIATION
Target $75.5
JEFF
Buy
Cambrex initiated with a Buy at Jefferies
Jefferies analyst David Windley started Cambrex (CBM) with a Buy rating and $75.50 price target. The analyst sees the company, as a leading manufacturer of small molecule active pharmaceutical ingredients, benefiting from increased API outsourcing. He adds that his Gilead (GILD) analysis, Cambrex's top customer, is "differentiated and positive."
10/01/18
CANT
10/01/18
INITIATION
Target $87
CANT
Overweight
Gilead initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Gilead Sciences with an Overweight rating and $87 price target.
CTRP Ctrip
$37.16

(0.00%)

05/21/18
THCP
05/21/18
UPGRADE
Target $50
THCP
Buy
Ctrip upgraded to Buy from Hold at TH Data Capital
TH Data Capital analyst Tian Hou upgraded Ctrip to Buy with a $50 price target. The analyst expects a traffic recovery to drive better Q1 results when Ctrip reports tomorrow. The company's business has "already stabilized and is on its way to recovery," Hou tells investors in a pre-earnings research note. He sees Q1 as the likely the bottom for Ctrip, and expects its results to recover in the rest of 2018.
07/13/18
GUGG
07/13/18
NO CHANGE
GUGG
Ctrip estiamtes reduced below conesnsus at Guggenheim
Guggenheim analyst Jake Fuller lowered Ctrip revenue estimates below consensus given ongoing headwinds from the recent service-oriented product changes and slowdown in May and June traffic trends from the strong April.
06/26/18
DAIW
06/26/18
UPGRADE
DAIW
Buy
Ctrip upgraded to Buy from Outperform at Daiwa
05/21/18
05/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Neutral from Sell at MoffettNathanson. 2. ProsHoldings (PROS) upgraded to Outperform from Market Perform at Northland with analyst Tim Klasell citing last week's annual user conference and analyst meetings. 3. Ctrip (CTRP) upgraded to Buy from Hold at TH Data Capital with analyst Tian Hou saying the company's business has "already stabilized and is on its way to recovery." 4. Sempra Energy (SRE) upgraded to Buy from Hold at Argus with analyst Jacob Kilstein citing anticipated earnings accretion from the recent purchase of a majority stake in Oncor, favorable regulations, and the growing base rate at its California utilities. 5. Dillard's (DDS) upgraded to Buy from Underperform at BofA/Merrill with analyst Heather Balsky saying she expects improved consumer sentiment, especially in the energy market, to support positive comps and drive multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MT ArcelorMittal
$31.14

0.28 (0.91%)

02/20/18
BOFA
02/20/18
UPGRADE
BOFA
Buy
ArcelorMittal upgraded to Buy from Neutral at BofA/Merrill
03/09/18
COWN
03/09/18
NO CHANGE
COWN
Cowen sees upside for entire steel group with tariff decision
Cowen analyst Novid Rassouli said he sees upside for the entire steel group following the announced decision on tariffs for imported steel and aluminum. He said the entire steel group is trading at a discount to current spot steel prices. The analyst also believes Century Aluminum (CENX) will be the biggest beneficiary on the aluminum side, as he sees it as the best vehicle to capitalize. Publicly traded companies in the steel space include U.S. Steel (X), Steel Dynamics (STLD), AK Steel (AKS), Cleveland-Cliffs (CLF), Nucor (NUE) and ArcelorMittal (MT).
04/30/18
JPMS
04/30/18
DOWNGRADE
JPMS
Neutral
Outokumpu downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Luke Nelson downgraded Outokumpu (OUTKY) to Neutral and lowered his price target for the shares to EUR 6 from EUR 11.60. ArcelorMittal (MT) remains the analyst's top pick in European Steel.
06/07/18
UBSW
06/07/18
DOWNGRADE
UBSW
Sell
ArcelorMittal downgraded to Sell from Buy at UBS
NEPT Neptune Wellness
$4.59

0.72 (18.60%)

SHPG Shire
$178.12

-3.19 (-1.76%)

09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
CREE Cree
$37.52

-0.34 (-0.90%)

09/11/18
ROTH
09/11/18
UPGRADE
ROTH
Buy
Cree upgraded to Buy from Neutral at Roth Capital
08/28/18
08/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. II-VI (IIVI) initiated with a Buy at Deutsche Bank while Cree (CREE) was initiated with a Hold. 2. Arlo Technologies (ARLO) initiated with an Outperform at Imperial Capital and Cowen, a Buy at Deutsche Bank, a Neutral at BofA/Merrill and Guggenheim, as well as a Market Perform at Raymond James. 3. AnaptysBio (ANAB) initiated with an Overweight at Cantor Fitzgerald. 4. Oshkosh (OSK) initiated with a Neutral at Buckingham. 5. nLight (LASR) initiated with a Sell at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/18
DBAB
08/28/18
INITIATION
Target $47
DBAB
Hold
Deutsche views Cree as fairly valued, initiates with Hold rating
Deutsche Bank analyst Sidney Ho last night initiated coverage of Cree with a Hold rating and $47 price target. The company's This transformation to focus on the fast-growing silicon carbide market has not gone unnoticed, with the stock nearly doubling since a year ago, Ho tells investors in a research note. The analyst believes Cree's current valuation seems to reflect most of its earnings growth potential. As such, he finds the stock fairly valued.
09/11/18
09/11/18
UPGRADE
Target $60

Buy
Cree upgraded to Buy on robust demand at Roth Capital
As previously reported, Roth Capital analyst Craig Irwin upgraded Cree to Buy from Neutral and raised his price target on the shares to $60 from $50 after attending the ECSCRM conference in Birmingham, U.K. The analyst notes that SiC chips OEMs talked quietly about approximately 50 new MOSFET programs that start ramping in 2019, where he expects Cree to retain strong share. While wafer pricing will see a long-term downward trajectory to facilitate growth, the analyst does not expect any sharp price drops, so technology and process changes should allow Wolfspeed's wafer business to preserve impressive gross margins.
IRDM Iridium
$22.65

0.15 (0.67%)

05/09/18
BWSF
05/09/18
INITIATION
Target $22
BWSF
Buy
Iridium initiated with a Buy at BWS Financial
BWS Financial analyst Hamed Khorsand started Iridium Communications with a Buy rating and $22 price target. The analyst views the satellite launch scheduled for May 19 as the "next immediate catalyst for the stock."
05/09/18
05/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) initiated with a Buy at Seaport Global. 2. Amneal Pharmaceuticals (AMRX) initiated with a Buy at Deutsche Bank. 3. Iridium (IRDM) initiated with a Buy at BWS Financial. 4. ServiceMaster (SERV) initiated with a Buy at Buckingham while Rollins (ROL) was initiated with a Neutral at Buckingham. 5. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/27/18
SIDC
08/27/18
DOWNGRADE
SIDC
Neutral
Iridium downgraded to Neutral from Buy at Sidoti
09/10/18
NORL
09/10/18
DOWNGRADE
Target $14
NORL
Underperform
Iridium downgraded to Underperform from Market Perform at Northland
Northland analyst Paul Penney downgraded Iridium to Underperform from Market Perform as he believes the stock's current price does not adequately account for a number of mounting risks, such as targets for its Certurs Broadband segment that he sees as ambitious and the uncertainty of the renewal of its contract with the Department of Defense. Penney lowered his price target on Iridium shares to $14 from $14.75.

TODAY'S FREE FLY STORIES

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

FN

Fabrinet

$55.23

0.67 (1.23%)

17:25
02/15/19
02/15
17:25
02/15/19
17:25
Hot Stocks
Fabrinet CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

UBER

Uber

$0.00

(0.00%)

17:24
02/15/19
02/15
17:24
02/15/19
17:24
Periodicals
Uber sues NYC over move to cap number of ride-hailing drivers, Bloomberg says »

Uber is suing New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

17:19
02/15/19
02/15
17:19
02/15/19
17:19
Periodicals
House Democrats to probe POTUS emergency declaration, Bloomberg says »

The House Judiciary…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$51.71

0.25 (0.49%)

17:11
02/15/19
02/15
17:11
02/15/19
17:11
Hot Stocks
Oracle authorizes additional $12B stock buyback under existing program »

In a regulatory 8K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

SBLK

Star Bulk Carriers

$8.21

0.13 (1.61%)

17:03
02/15/19
02/15
17:03
02/15/19
17:03
Hot Stocks
Star Bulk Carriers acquires 95,605 of its common shares »

Star Bulk Carriers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLI

Hollysys

$20.56

0.26 (1.28%)

17:02
02/15/19
02/15
17:02
02/15/19
17:02
Earnings
Hollysys reports Q2 adjusted EPS 73c, consensus 59c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

AKS

AK Steel

$2.98

-0.015 (-0.50%)

16:58
02/15/19
02/15
16:58
02/15/19
16:58
Syndicate
Breaking Syndicate news story on AK Steel »

AK Steel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
02/15/19
02/15
16:55
02/15/19
16:55
General news
Treasury Market Summary: i »

Treasury Market Summary:…

LPTX

Leap Therapeutics

$1.65

(0.00%)

16:53
02/15/19
02/15
16:53
02/15/19
16:53
Hot Stocks
Valence Helix Investments discloses 10.99% stake in Leap Therapeutics »

Valence Helix disclosed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$23.25

-0.24 (-1.02%)

16:52
02/15/19
02/15
16:52
02/15/19
16:52
Hot Stocks
Mid Penn Bancorp seeks approval to relocate Allentown Boulevard branch »

Mid Penn Bank, subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$423.79

8.54 (2.06%)

, AMGN

Amgen

$188.31

1.6 (0.86%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
Regeneron says EPO revokes Immunex's European patent No. 2,990,420 »

Regeneron…

REGN

Regeneron

$423.79

8.54 (2.06%)

AMGN

Amgen

$188.31

1.6 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 28

    Apr

  • 13

    May

UPS

UPS

$110.89

-0.91 (-0.81%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
UPS CFO sells 9.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DAL

Delta Air Lines

$51.09

0.58 (1.15%)

16:43
02/15/19
02/15
16:43
02/15/19
16:43
Syndicate
Breaking Syndicate news story on Delta Air Lines »

Delta Air Lines files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.89

-0.91 (-0.81%)

16:42
02/15/19
02/15
16:42
02/15/19
16:42
Hot Stocks
UPS raises quarterly dividend to 96c per share from 91c »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.